International Journal of Pharmaceutics最新文献

{"title":"Oxygen Sensitive Drug Release Using Hemoglobin Microbubbles: A New Approach to Targeting Hypoxia in Ultrasound-Mediated Drug Delivery","authors":"Ghazal Rastegar,&nbsp;Mohammad Musa Salman,&nbsp;Shashank R. Sirsi","doi":"10.1016/j.ijpharm.2025.125521","DOIUrl":"10.1016/j.ijpharm.2025.125521","url":null,"abstract":"<div><div>Targeted drug delivery strategies using focused ultrasound (FUS) are gaining prominence in clinical application. FUS offers deep tissue penetration and precise targeting capabilities. The capabilities of FUS in targeted drug delivery are greatly enhanced by the introduction of ultrasound contrast agents (UCAs – also known as microbubbles). This study introduces a novel hypoxia-targeting drug delivery system using hemoglobin microbubbles (HbMBs) conjugated with doxorubicin-loaded liposomes (LDOX). Previously, we reported that HbMBs exhibit significant acoustic response differences between oxygenated and deoxygenated environments due to hemoglobin’s conformational changes, which alters the MBs’ shell elasticity as well as resonance frequency. In this study, we coated the surface of HBMBs with LDOX to create Lip-HBMB complex and subsequently investigated its drug release at different oxygen partial pressures (pO₂) when exposed to an ultrasound field. Results showed significantly higher drug release at lower oxygen levels, with about 10-times higher release at 5 mmHg pO₂ than 160 mmHg pO₂ at 0.5 W/cm² US intensity and 3 MHz frequency. This highlights Lip-HbMBs’ potential for targeted drug delivery to hypoxic tumor regions, marking a significant advancement in focused ultrasound-mediated drug delivery. This study marks the first-ever report of ultrasound-mediated oxygen-sensitive drug uncaging, which holds promise in enhancing FUS specificity and addressing the challenges posed by metastatic cancer.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125521"},"PeriodicalIF":5.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and delivery effect of prolonged-retention dexamethasone and tacrolimus microcrystals eye drops","authors":"Ji Huang ,&nbsp;Siying Yuan ,&nbsp;Jinlan Mao ,&nbsp;Kangyiran Pan ,&nbsp;Li Liu ,&nbsp;Ilva D. Rupenthal ,&nbsp;Qinqiang Long ,&nbsp;Lin He ,&nbsp;Qinyu Li ,&nbsp;Lirong Guo ,&nbsp;Suling Bei ,&nbsp;Tianying Huang ,&nbsp;Xifeng Teng ,&nbsp;Xiao Yu ,&nbsp;Dongzhi Hou","doi":"10.1016/j.ijpharm.2025.125518","DOIUrl":"10.1016/j.ijpharm.2025.125518","url":null,"abstract":"<div><div>The improvement of drug solubility is essential for enhancing drug absorption of eye drops, particularly for poorly soluble drugs. In this study, drug crystallization techniques were utilized to synthesize dexamethasone microcrystals (DES MCs) and tacrolimus microcrystals (TAM MCs). To further enhance the retention of the MCs, DES MCs@(PEI/HA)₃ and TAM MCs@(PEI/HA)₃ were prepared by the alternate deposition of polyethyleneimine (PEI) and hyaluronic acid (HA) on the surface of the MCs through electrostatic adsorption. The sustained release effect of TAM MCs@(PEI/HA)₃, resulting from enhanced solubility through micro-crystallization, was confirmed via solubility measurements and in vitro release studies. Similarly, DES MCs@(PEI/HA)₃ exhibited comparable sustained release properties. Subsequently, the hydrophobicity, safety, and efficacy of DES MCs@(PEI/HA)₃ and TAM MCs@(PEI/HA)₃ were investigated through the in vitro and in vivo experiments. Notably, TAM MCs@(PEI/HA)₃ demonstrated superior efficacy over commercially available TALYMUS®, enabling a once-daily dosing regimen. In conclusion, microcrystal preparation exhibited a more significant impact on the delivery of tacrolimus compared to dexamethasone. The TAM MCs@(PEI/HA)₃ microcrystals suspension eye drops prepared using the layer-by-layer self-assembly technique, offer a promising strategy for enhancing the solubility of poorly soluble drugs and ocular drug delivery.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125518"},"PeriodicalIF":5.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements of nanoscale drug formulations for combination treatment of colorectal cancer","authors":"Liqi Li ,&nbsp;Maohua Chen ,&nbsp;Rui L. Reis ,&nbsp;Subhas C. Kundu ,&nbsp;Bo Xiao ,&nbsp;Xiaoxiao Shi","doi":"10.1016/j.ijpharm.2025.125508","DOIUrl":"10.1016/j.ijpharm.2025.125508","url":null,"abstract":"<div><div>Combination chemotherapy is widely utilized in treating colorectal cancer (CRC), particularly for patients who are ineligible for surgery or those with metastatic CRC (mCRC). While this therapeutic method has demonstrated efficacy in managing CRC and mCRC, its broader clinical application is limited due to the unique physical properties, mechanisms of action, and pharmacokinetics of different chemotherapeutic drugs. Consequently, achieving satisfactory treatment outcomes proves to be challenging. Nanotechnology has given rise to innovative drug systems that are precise, controllable, and highly efficient in drug delivery. These nanoscale drug delivery systems can integrate the advantageous aspects of various therapeutic modalities, including chemotherapy, gene therapy, and immunotherapy. This review aims to explain the application of nano-drug delivery system in the treatment of colorectal cancer. Through its unique physical/chemical properties and biological functions, it can solve the limitations of traditional therapy and achieve more accurate, efficient and safe treatment. The advantages/disadvantages, physical and chemical characteristics of various drug delivery systems are described in detail, and suggestions on selecting reasonable NDDSs according to different drug combination methods are given to achieve the best therapeutic effect. This review paper presents an exhaustive summary of the diverse range of drugs utilized in chemotherapy, in addition to outlining strategies for effectively integrating chemotherapy with other treatment modalities. Furthermore, it delves into the principle of selecting carriers for various drug combinations.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125508"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin-loaded bioinspired mesoporous silica nanoparticles for targeted melanoma therapy: Nanotopographical design with in vitro and in vivo evaluation","authors":"Omar A. Elkady ,&nbsp;Mai A. Zaafan ,&nbsp;Marian George ,&nbsp;Nadeen Ashraf Elsayed ,&nbsp;Verina Ghaly Mettias ,&nbsp;Verina Sameh Edward ,&nbsp;Dina Saeed Ghataty","doi":"10.1016/j.ijpharm.2025.125499","DOIUrl":"10.1016/j.ijpharm.2025.125499","url":null,"abstract":"<div><div>Bioinspired nanotopographical carriers have emerged as innovative cancer therapy strategies, mimicking natural processes to enhance targeted delivery and reduce systemic toxicity. This study presents the development of virus-like mesoporous silica nanoparticles (MSN) as a delivery platform for repurposed metformin (MTF) in a topical multi-stimuli responsive system for melanoma treatment. Metformin-loaded virus-like MSN (MTF-MSN) were fabricated and incorporated into a thermo-responsive gelling system. The particles were evaluated for morphology, zeta potential (ZP), particle size (PS), entrapment efficiency (EE%), Fourier-transform infrared (FT-IR) spectroscopy, MTT cytotoxicity assay, <em>in vitro</em> release, and in a melanoma <em>in vivo</em> model. The particles exhibited a spherical morphology, a zeta potential of +31.9 ± 1.45 mV, and a particle size of 197 ± 3.47 nm, ideal for skin penetration. MTF-MSN demonstrated significant antiproliferative activity against melanoma A375 cells, with lower IC₅₀ values (192 μg/mL) compared to free MTF (&gt;300 μg/mL). Sustained, pH-sensitive MTF release was observed over 48 h at pH 7.4 and 6 h at pH 5.5. In vivo studies showed enhanced anti-cancer efficacy of MTF-MSN, evidenced by elevated caspase-3 and Neurofibromin Type-1 (NF-1) levels, along with suppressed angiogenesis markers VEGF and NRAS. The MTF-MSN-treated group exhibited superior outcomes compared to free MTF and controls (p &lt; 0.05). This innovative bioinspired MTF-MSN hydrogel system optimizes MTF delivery for melanoma therapy, pioneering advancements in drug repurposing and nano-oncology.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125499"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cubosomes-based hydrogels; A promising advancement for drug delivery","authors":"Sara Khoshdooz ,&nbsp;Parisa Khoshdooz ,&nbsp;Reihaneh Bonyad ,&nbsp;Ali Bonyad ,&nbsp;Sina Sheidaei ,&nbsp;Rahim Nosrati","doi":"10.1016/j.ijpharm.2025.125510","DOIUrl":"10.1016/j.ijpharm.2025.125510","url":null,"abstract":"<div><div>Hydrogels have so far shown promising opportunities for possible drug delivery applications. Cubosomes (Cub), bicontinuous cubic phase liquid crystals, possess several characteristics that make them appealing as a versatile medium for drug administration. They have been regarded as prospective nanocarriers for drugs, offering a promising alternative to liposomes as a drug delivery method. Cub have the ability to encapsulate lipophilic, hydrophilic, and amphiphilic medicines. Hydrogels have recently shown significant interest in using Cub-based formulations. This paper examines the current advancements in biodegradable Cub-based hydrogels (Cubogel) for intelligent medication delivery to various organs. In conclusion, this paper briefly discusses the prospects and problems of hydrogels based on Cub.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125510"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and development of Dasatinib nanoemulsions for ocular delivery: In vitro characterization, biocompatibility, and Ex vivo ocular irritation study","authors":"Richa Khadke,&nbsp;Amol Shete,&nbsp;Akanksha Dashawant","doi":"10.1016/j.ijpharm.2025.125504","DOIUrl":"10.1016/j.ijpharm.2025.125504","url":null,"abstract":"<div><div>Dasatinib, a potent tyrosine kinase inhibitor with dual anti-inflammatory and anti-angiogenic properties, holds significant potential for treating ocular diseases such as Corneal Neovascularization (CNV), uveitis, and diabetic retinopathy. However, its low aqueous solubility and limited ocular retention present major formulation challenges. This study concentrated on the design and evaluation of Dasatinib nanoemulsions (Dasa NEs) for ocular delivery, utilizing nanotechnology to enhance solubility, stability, and therapeutic efficacy. The Dasa NEs were prepared using Oleic acid (lipid phase), Tween 80, Propylene Glycol (PG) (Smix), with component ratios optimized through pseudo-ternary phase diagrams. The resulting formulations exhibited nanoscale droplet sizes (&lt;100 nm), low polydispersity indices, and stable zeta potential, ensuring colloidal stability and efficient delivery. Comprehensive physicochemical evaluations confirmed that the NEs possessed ideal pH, refractive index, surface tension, and viscosity for ophthalmic applications. Biocompatibility assessments using the MTT assay on SIRC cells demonstrated high cell viability, while HET-CAM tests confirmed the absence of significant ocular irritation. <em>In vitro</em> diffusion studies indicated improved drug permeation, highlighting the potential for prolonged therapeutic effects. Stability studies further validated the robustness of the formulations under various conditions. The developed nanoemulsions offer a promising, non-invasive platform for ocular drug delivery, improving patient compliance and therapeutic outcomes. Future studies should focus on in vivo evaluations and long-term safety to advance the clinical translation of this novel formulation.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125504"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclodextrin-based formulations for delivering broad-spectrum nerve agent antidote to the central nervous system: stability, physicochemical characterization and application in a human blood–brain barrier model","authors":"Léa Thiberville ,&nbsp;Vincent Faivre ,&nbsp;Christina Sizun ,&nbsp;Marie-Pierre Dehouck ,&nbsp;Christophe Landry ,&nbsp;Rachid Baati ,&nbsp;Nicolas Tsapis","doi":"10.1016/j.ijpharm.2025.125505","DOIUrl":"10.1016/j.ijpharm.2025.125505","url":null,"abstract":"<div><div>Nerve agents, such as VX and sarin, represent a significant threat to global security due to their devastating neurotoxic effects and potential for misuse. The therapeutic inefficacy of current countermeasures underscores the urgent need for more effective alternatives. In this context, recent advances have identified JDS364.HCl, an uncharged hybrid antidote, as a promising candidate. However, its instability in aqueous solution remains a significant challenge. To address this, cyclodextrin-based formulations were developed using two EMA-approved cyclodextrins: HP-β-CD and SBE-β-CD. These formulations significantly improved JDS364.HCl stability for over two months at room temperature. Interaction studies revealed a 1:1 stoichiometry for both cyclodextrin complexes, with JDS364.HCl: SBE-β-CD exhibiting a 100-fold higher affinity constant, attributed to additional electrostatic interactions with SBE-β-CD sidechains. While SBE-β-CD provided superior plasma stability compared to HP-β-CD, the high binding affinity of JDS364.HCl: SBE-β-CD complexes hindered the molecule’s release and reduced its ability to cross the BBB, as observed in a human BBB model. Nonetheless, the results for both cyclodextrins are encouraging, as they enhance JDS364.HCl’s stability in plasma while allowing its passage across the BBB. Notably, JDS364.HCl demonstrated superior BBB permeability compared to marketed antidotes such as 2-PAM. These findings highlight the potential of cyclodextrins to improve the efficacy of JDS364.HCl as a nerve agent antidote.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125505"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of vacuum compression molded tablets with rapid drug release and a comparison of dissolution profiles between molded and FDM 3D-printed tablets","authors":"Nirali G. Patel ,&nbsp;Hari P. Kandagatla ,&nbsp;Daniel Treffer ,&nbsp;Abu T.M. Serajuddin","doi":"10.1016/j.ijpharm.2025.125511","DOIUrl":"10.1016/j.ijpharm.2025.125511","url":null,"abstract":"<div><div>In recent years, there has been much interest in the development of personalized and on-demand tablets by FDM 3D-printing of melt-extruded filaments. Alternatively, the filaments can also be converted into molded tablets. However, drug release rates from tablets produced by both methods are very slow and not amenable to immediate-release drug products. We previously reported a novel approach called acid-base supersolubilization (ABS), whereby dissolution rates of poorly water-soluble basic drugs from FDM 3D-printed tablets could be greatly increased by interaction with added weak acids. Here, we investigated whether such acid-base interaction applying the ABS principle could similarly increase drug dissolution rates from molded tablets. Haloperidol, a basic drug with low and pH-dependent solubility, was used as the model drug, and molded tablets were prepared by the vacuum compression molding (VCM), where filaments containing 1:1 and 1:2 molar ratios of haloperidol and malic acid along with Kollidon VA64 were prepared at 15 % w/w drug loading. Broken filaments were compressed into VCM tablets under a vacuum at high temperatures. The tablets thus produced gave very high pH-independent dissolution rates, with &gt; 90 % haloperidol dissolving in 60 min. Dissolution rates were similar from both molded and FDM 3D-printed tablets, and thus, the two methods can be used interchangeably depending on the drug development needs.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125511"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetazolamide-loaded intravitreal implants for the treatment of glaucoma: formulation, physicochemical characterization and assessment of in vitro and in vivo safety","authors":"Pedro Henrique Reis da Silva ,&nbsp;Matheus Augusto de Castro ,&nbsp;Marcela Coelho Silva Ribeiro ,&nbsp;Lorena Thalia Araújo Gonçalves ,&nbsp;Lutiana Amaral de Melo ,&nbsp;Maria Betânia Freitas-Marques ,&nbsp;Tércio Assunção Pedrosa ,&nbsp;Gérson Antônio Pianetti ,&nbsp;Sílvia Ligorio Fialho ,&nbsp;Maria Irene Yoshida ,&nbsp;Wagner da Nova Mussel ,&nbsp;Armando Silva-Cunha ,&nbsp;Christian Fernandes","doi":"10.1016/j.ijpharm.2025.125507","DOIUrl":"10.1016/j.ijpharm.2025.125507","url":null,"abstract":"<div><div>Glaucoma is a leading cause of permanent blindness, currently affecting over 75 million individuals worldwide. Treatments primarily aim to lower intraocular pressure (IOP), with acetazolamide being a common pharmacotherapy. However, systemic side effects and poor bioavailability limit its clinical effectiveness. This study presents the development and physicochemical and safety evaluation of biodegradable intravitreal implants loaded with acetazolamide using polylactic-co-glycolic acid (PLGA), designed to enhance targeted drug delivery directly to the vitreous humor. The acetazolamide-loaded PLGA implants were successfully fabricated via hot molding, yielding cylindrical rods measuring 5.00 ± 0.02 mm in diameter. Incorporation efficiency reached approximately 92 %, with a uniform drug dose of 230 μg/g. Comprehensive physicochemical characterization confirmed compatibility between the drug and polymer, with stability demonstrated for at least 6 months. The implants exhibited a biphasic drug release profile, sustaining approximately 50 % of the drug over 42 days without an initial burst, indicating their potential for effective and prolonged glaucoma management. Safety assessments revealed that the implants did not induce retinal toxicity at doses up to 0.020 mmol/L. In vitro cytotoxicity assays with ARPE-19 cells and in vivo tests − electroretinography, Goldmann applanation tonometry, optical coherence tomography, and histological analysis − showed no adverse effects on retinal function or structure. Importantly, the implants significantly reduced IOP in normotensive rabbits, confirming their therapeutic potential. This innovative approach represents a promising alternative for glaucoma treatment, addressing the limitations of current modalities while providing sustained drug delivery and enhanced safety.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125507"},"PeriodicalIF":5.3,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced drug release control in coaxial electrospun fibers via heat pressing: Reducing burst release and achieving dual-phase delivery","authors":"Ji-Feng Wang,&nbsp;Jin-Jia Hu","doi":"10.1016/j.ijpharm.2025.125501","DOIUrl":"10.1016/j.ijpharm.2025.125501","url":null,"abstract":"<div><div>Burst release is a common challenge in drug delivery systems (DDS), potentially leading to subtherapeutic or toxic drug concentrations. Coaxial electrospinning has emerged as a promising technique to address this issue by encapsulating drugs within core-sheath fiber structures, thereby preventing direct exposure of the drug to the environment and ensuring a gradual release profile. However, secondary processing of coaxial electrospun membranes, such as cutting or slicing, can damage the core-sheath structure of fibers, exposing the drug-loaded core and exacerbating burst release. In this study, we applied heat pressing along the intended cutting line prior to cutting, aiming to thermally seal the core-sheath structure of fibers and prevent drug leakage from the core at cut edges. As a result, the heat-pressed group exhibited a significantly reduced initial burst release followed by a more sustained release compared to the control group, which involved no heat pressing before cutting. The release profiles of both groups were well described by the Korsmeyer-Peppas model with n = 0.32 (R² = 0.95) for the control group and n = 0.49 (R² = 0.99) for the heat-pressed group. Notably, the release behavior of the heat-pressed group exhibited a closer approximation (R² = 0.96) to a first-order model compared to the control group (R² = 0.59). Furthermore, we successfully developed a dual-phase DDS by manipulating the ratio of unsealed (fast release) and sealed (slow release) portions of an electrospun membrane. In conclusion, heat pressing presents a simple yet effective strategy for enhancing the performance and reliability of coaxial electrospun DDS, offering potential for broader applications in controlled drug delivery.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"674 ","pages":"Article 125501"},"PeriodicalIF":5.3,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}